Highly active antiretroviral therapies (HAART) is incapable of fully eradicating virus within an adult patient, due to the persistence of latently infected resting CD4+ T lymphocytes and infected macrophages and monocytes, which may produce low levels of viremia without dying. Recently, there has been a growing interest in using gene therapy as an alternative to HAART, particularly with the recent breakthrough of the Berlin patient, who was functionally cured of HIV after receiving an allogeneic bone marrow transplant with CCR5-defective hematopoietic stem cells. Indeed, we have conducted the only clinical trial to date to test an anti-HIV RNAi therapeutic, which required the ex vivo delivery of a lentiviral vector in autologous CD34+ hematopoietic stem cells for patients with AIDS-related lymphoma. However, for RNAi-based therapeutics to become available for the vast majority of HIV patients, alternative systemic delivery methods must be developed. In this project, we will test three promising methods for delivering anti-HIV siRNAs: an anti-gp120 RNA aptamer-siRNA conjugate for targeted delivery into cells actively infected with HIV; an anti-CD4 RNA aptamer-siRNA conjugate for targeted delivery into CD4+ T cells and macrophages; and a cationic PAMAM dendrimer-siRNA nanoparticle for systemic delivery.
For Aim 1, we will elucidate the molecular interactions between the anti-gp120 aptamer and HIV gp120 protein using surface plasmon resonance, X-ray crystallography, and electron microscopy.
In Aim2 of this project, we will use positron emission tomography and near-infrared fluorescence imaging to measure the dose- dependent biodistribution and whole-body clearance of our RNA-based therapeutics in a humanized mouse model.
In Aim 3, we will conduct a series of in vivo experiments in HIV-infected humanized mice to test the efficacy of individual and combination RNA-based therapies. These experiments will test siRNAs that target endogenous genes required for HIV infection (prophylactic and entry inhibitor siRNAs), mechanisms required for the persistence of latency (anti-latency siRNAs), and genes required for cell survival (cytotoxic siRNAs). Hence, we will test a comprehensive, RNA-based shock and kill strategy that aims to purge the latent reservoir, eliminate the cells actively infected with HIV, and protect cells from new infection. In addition to standard assays for detecting HIV viremia, we will use droplet digital PCR to measure the levels of integrated provirus in treated and non-treated animals. In summary, this project represents an innovative approach for suppressing and potentially eradicating HIV infection. Moreover, the aims of this pre-clinical study will establish an important benchmark for evaluating RNAi- based therapy as a treatment for HIV.
Recent advances in RNAi-based drugs have broadened the scope of therapeutic targets for a variety of human disease. We have designed a new systemic delivery approach for a cocktail of anti-HIV siRNAs using chemically synthesized, ligand-specific RNA aptamers or cationic PAMAM dendrimer nanoparticles. We will test these RNA therapies in a pre-clinical investigation in humanized mice by monitoring the biodistribution, whole-body clearance, and off-target toxicity. In addition, we will perform functional analyses in HIV-infecte mice to examine the potential eradication of latent reservoirs and prophylactic treatment of siRNAs pre- and post-HIV challenge.
|Yoon, Sorah; Armstrong, Brian; Habib, Nagy et al. (2017) Blind SELEX Approach Identifies RNA Aptamers That Regulate EMT and Inhibit Metastasis. Mol Cancer Res 15:811-820|
|Yoon, Sorah; Rossi, John J (2017) Future strategies for the discovery of therapeutic aptamers. Expert Opin Drug Discov 12:317-319|
|Zhou, Jiehua; Rossi, John (2017) Aptamers as targeted therapeutics: current potential and challenges. Nat Rev Drug Discov 16:181-202|
|Yoon, Sorah; Rossi, John J (2017) Emerging cancer-specific therapeutic aptamers. Curr Opin Oncol 29:366-374|
|Song, Min-Sun; Rossi, John J (2017) Molecular mechanisms of Dicer: endonuclease and enzymatic activity. Biochem J 474:1603-1618|
|Yoon, Sorah; Huang, Kai-Wen; Reebye, Vikash et al. (2017) Aptamer-Drug Conjugates of Active Metabolites of Nucleoside Analogs and Cytotoxic Agents Inhibit Pancreatic Tumor Cell Growth. Mol Ther Nucleic Acids 6:80-88|
|Yoon, Sorah; Huang, Kai-Wen; Reebye, Vikash et al. (2016) Targeted Delivery of C/EBP? -saRNA by Pancreatic Ductal Adenocarcinoma-specific RNA Aptamers Inhibits Tumor Growth In Vivo. Mol Ther 24:1106-1116|
|Takahashi, Mayumi; Wu, Xiwei; Ho, Michelle et al. (2016) High throughput sequencing analysis of RNA libraries reveals the influences of initial library and PCR methods on SELEX efficiency. Sci Rep 6:33697|
|Cui, Qi; Yang, Su; Ye, Peng et al. (2016) Downregulation of TLX induces TET3 expression and inhibits glioblastoma stem cell self-renewal and tumorigenesis. Nat Commun 7:10637|
|Zhou, Jiehua; Rossi, John J (2016) Evolution of Cell-Type-Specific RNA Aptamers Via Live Cell-Based SELEX. Methods Mol Biol 1421:191-214|
Showing the most recent 10 out of 159 publications